{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-031603","form_type":"8-K","ticker":"ADTX","cik":"0001726711","company_name":"Aditxt, Inc.","filed_at":"2025-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.485657+00:00","generated_at":"2026-05-23T15:33:41.904534+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aditxt regains Nasdaq minimum bid price compliance, removes panel monitoring","bullets":["Regained full compliance with Nasdaq listing requirements; no longer under panel monitoring.","Adimune subsidiary targeting IND/CTA filing for human trials in Q3/Q4 2025 for psoriasis and Type 1 diabetes.","Pearsanta plans commercial launch of prostate cancer and endometriosis tests in H2 2025.","Working to close Appili and Evofem acquisitions; capital and restructuring needed.","CEO reports approximately 40,000-50,000 shareholders globally."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-031603","json":"https://secwatch.observer/filing/0001213900-25-031603.json","markdown":"https://secwatch.observer/filing/0001213900-25-031603.md","text":"https://secwatch.observer/filing/0001213900-25-031603.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1726711/000121390025031603/0001213900-25-031603-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1726711/000121390025031603/ea0238058-8k_aditxtinc.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T15:33:41.904534+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}